25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aridis Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Aridis Pharmaceuticals Inc together

I guess you are interested in Aridis Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aridis Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aridis Pharmaceuticals Inc

I send you an email if I find something interesting about Aridis Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Aridis Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aridis Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
25.0%

What is your share worth?

Current worth
$-0.54
Expected worth in 1 year
$-1.45
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.91
Return On Investment
-908,332.2%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0001
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aridis Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-9.82 - $-6.29
Total Value Per Share
$-10.36 - $-6.84

2.2. Growth of Aridis Pharmaceuticals Inc (5 min.)




Is Aridis Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$24.2m-$14.1m-$10.1m-41.8%

How much money is Aridis Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$30.7m-$42.2m$11.5m37.5%
Net Profit Margin-159.7%-2,754.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Aridis Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aridis Pharmaceuticals Inc?

Welcome investor! Aridis Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Aridis Pharmaceuticals Inc.

First you should know what it really means to hold a share of Aridis Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Aridis Pharmaceuticals Inc is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aridis Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aridis Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.54. Based on the TTM, the Book Value Change Per Share is $-0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aridis Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.69-689,841.6%-0.69-689,841.6%-1.04-1,039,170.8%-0.68-684,457.3%-0.55-552,684.9%
Usd Book Value Change Per Share-0.23-227,083.1%-0.23-227,083.1%-0.12-121,797.5%-0.16-160,039.5%-0.07-67,954.4%
Usd Dividend Per Share0.000.0%0.000.0%0.0992,587.6%0.0224,606.3%0.0215,378.9%
Usd Total Gains Per Share-0.23-227,083.1%-0.23-227,083.1%-0.03-29,209.9%-0.14-135,433.2%-0.05-52,575.5%
Usd Price Per Share1.18-1.18-2.33-5.02-3.14-
Price to Earnings Ratio-1.71--1.71--2.24--8.76--5.48-
Price-to-Total Gains Ratio-5.20--5.20--79.77--17.05--17.05-
Price to Book Ratio-2.17--2.17--7.36-6.53-4.08-
Price-to-Total Gains Ratio-5.20--5.20--79.77--17.05--17.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.23-0.16
Usd Total Gains Per Share-0.23-0.14
Gains per Quarter (10000000 shares)-2,270,830.53-1,354,332.12
Gains per Year (10000000 shares)-9,083,322.12-5,417,328.49
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9083322-9083332984251-6401579-5417338
20-18166644-181666541968502-12803159-10834666
30-27249966-272499762952753-19204738-16251994
40-36333288-363332983937004-25606318-21669322
50-45416611-454166204921255-32007897-27086650
60-54499933-544999425905505-38409476-32503978
70-63583255-635832646889756-44811056-37921306
80-72666577-726665867874007-51212635-43338634
90-81749899-817499088858258-57614215-48755962
100-90833221-908332309842509-64015794-54173290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.08.00.00.0%0.08.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.06.00.025.0%2.06.00.025.0%
Dividend per Share0.00.01.00.0%1.00.02.033.3%2.00.03.040.0%2.00.06.025.0%2.00.06.025.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.06.00.025.0%2.06.00.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aridis Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.227-0.2270%-0.122-46%-0.160-30%-0.068-70%
Book Value Per Share---0.544-0.5440%-0.317-42%-0.077-86%0.017-3270%
Current Ratio--0.3150.3150%0.804-61%1.563-80%3.219-90%
Debt To Asset Ratio--2.6492.6490%1.527+74%1.357+95%1.158+129%
Debt To Equity Ratio----0%-0%1.379-100%1.106-100%
Dividend Per Share----0%0.093-100%0.025-100%0.015-100%
Enterprise Value--18546320.00018546320.0000%82937420.000-78%212933576.000-91%212933576.000-91%
Eps---0.690-0.6900%-1.039+51%-0.684-1%-0.553-20%
Ev To Ebitda Ratio---0.629-0.6290%-1.867+197%-4.221+572%-4.221+572%
Ev To Sales Ratio--0.9630.9630%54.031-98%137.377-99%137.377-99%
Free Cash Flow Per Share---0.655-0.6550%-0.526-20%-0.479-27%-0.380-42%
Free Cash Flow To Equity Per Share---0.324-0.3240%0.252-228%-0.083-74%0.008-4040%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---6.291--------
Intrinsic Value_10Y_min---9.817--------
Intrinsic Value_1Y_max---0.513--------
Intrinsic Value_1Y_min---0.666--------
Intrinsic Value_3Y_max---1.631--------
Intrinsic Value_3Y_min---2.288--------
Intrinsic Value_5Y_max---2.857--------
Intrinsic Value_5Y_min---4.212--------
Market Cap4457.400-1179900%52597320.00052597320.0000%103857420.000-49%223939776.000-77%139962360.000-62%
Net Profit Margin---1.597-1.5970%-27.545+1624%-17.571+1000%-15.388+863%
Operating Margin---1.558-1.5580%-28.476+1728%-18.054+1059%-14.174+810%
Operating Ratio--1.5581.5580%28.476-95%20.197-92%16.741-91%
Pb Ratio0.000+100%-2.171-2.1710%-7.361+239%6.528-133%4.080-153%
Pe Ratio0.000+100%-1.711-1.7110%-2.242+31%-8.764+412%-5.477+220%
Price Per Share0.000-1179900%1.1801.1800%2.330-49%5.024-77%3.140-62%
Price To Free Cash Flow Ratio0.000+100%-1.801-1.8010%-4.426+146%-12.565+598%-7.853+336%
Price To Total Gains Ratio0.000+100%-5.196-5.1960%-79.768+1435%-17.046+228%-17.046+228%
Quick Ratio--0.1660.1660%0.606-73%1.429-88%3.120-95%
Return On Assets---2.092-2.0920%-1.578-25%-1.377-34%-1.288-38%
Return On Equity----0%-0%-1.7620%-1.4470%
Total Gains Per Share---0.227-0.2270%-0.029-87%-0.135-40%-0.053-77%
Usd Book Value---24232000.000-24232000.0000%-14110000.000-42%-3414600.000-86%764375.000-3270%
Usd Book Value Change Per Share---0.227-0.2270%-0.122-46%-0.160-30%-0.068-70%
Usd Book Value Per Share---0.544-0.5440%-0.317-42%-0.077-86%0.017-3270%
Usd Dividend Per Share----0%0.093-100%0.025-100%0.015-100%
Usd Eps---0.690-0.6900%-1.039+51%-0.684-1%-0.553-20%
Usd Free Cash Flow---29209000.000-29209000.0000%-23466000.000-20%-21359800.000-27%-16956750.000-42%
Usd Free Cash Flow Per Share---0.655-0.6550%-0.526-20%-0.479-27%-0.380-42%
Usd Free Cash Flow To Equity Per Share---0.324-0.3240%0.252-228%-0.083-74%0.008-4040%
Usd Market Cap4457.400-1179900%52597320.00052597320.0000%103857420.000-49%223939776.000-77%139962360.000-62%
Usd Price Per Share0.000-1179900%1.1801.1800%2.330-49%5.024-77%3.140-62%
Usd Profit---30749000.000-30749000.0000%-42281000.000+38%-29290800.000-5%-23466750.000-24%
Usd Revenue--19250000.00019250000.0000%1535000.000+1154%5112800.000+277%3944375.000+388%
Usd Total Gains Per Share---0.227-0.2270%-0.029-87%-0.135-40%-0.053-77%
 EOD+2 -6MRQTTM+0 -0YOY+10 -265Y+9 -2810Y+9 -28

3.3 Fundamental Score

Let's check the fundamental score of Aridis Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than0-1.597
Operating Margin (MRQ)Greater than0-1.558
Quick Ratio (MRQ)Greater than10.166
Current Ratio (MRQ)Greater than10.315
Debt to Asset Ratio (MRQ)Less than12.649
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-2.092
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Aridis Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.976
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.003
OpenGreater thanClose0.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Fundamental data was last updated by Penke on 2024-11-15 11:06:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aridis Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aridis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -159.7% means that $-1.60 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aridis Pharmaceuticals Inc:

  • The MRQ is -159.7%. The company is making a huge loss. -2
  • The TTM is -159.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-159.7%TTM-159.7%0.0%
TTM-159.7%YOY-2,754.5%+2,594.7%
TTM-159.7%5Y-1,757.1%+1,597.4%
5Y-1,757.1%10Y-1,538.8%-218.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-159.7%-112.2%-47.5%
TTM-159.7%-221.4%+61.7%
YOY-2,754.5%-210.0%-2,544.5%
5Y-1,757.1%-342.2%-1,414.9%
10Y-1,538.8%-464.5%-1,074.3%
4.3.1.2. Return on Assets

Shows how efficient Aridis Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aridis Pharmaceuticals Inc to the Biotechnology industry mean.
  • -209.2% Return on Assets means that Aridis Pharmaceuticals Inc generated $-2.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aridis Pharmaceuticals Inc:

  • The MRQ is -209.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -209.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-209.2%TTM-209.2%0.0%
TTM-209.2%YOY-157.8%-51.5%
TTM-209.2%5Y-137.7%-71.6%
5Y-137.7%10Y-128.8%-8.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-209.2%-11.3%-197.9%
TTM-209.2%-11.7%-197.5%
YOY-157.8%-11.3%-146.5%
5Y-137.7%-12.7%-125.0%
10Y-128.8%-14.1%-114.7%
4.3.1.3. Return on Equity

Shows how efficient Aridis Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aridis Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Aridis Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aridis Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-176.2%+176.2%
5Y-176.2%10Y-144.7%-31.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--15.9%+15.9%
YOY--14.3%+14.3%
5Y-176.2%-18.5%-157.7%
10Y-144.7%-19.3%-125.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aridis Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aridis Pharmaceuticals Inc is operating .

  • Measures how much profit Aridis Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aridis Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -155.8% means the company generated $-1.56  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aridis Pharmaceuticals Inc:

  • The MRQ is -155.8%. The company is operating very inefficient. -2
  • The TTM is -155.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-155.8%TTM-155.8%0.0%
TTM-155.8%YOY-2,847.6%+2,691.8%
TTM-155.8%5Y-1,805.4%+1,649.6%
5Y-1,805.4%10Y-1,417.4%-388.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-155.8%-222.9%+67.1%
TTM-155.8%-310.7%+154.9%
YOY-2,847.6%-223.5%-2,624.1%
5Y-1,805.4%-387.1%-1,418.3%
10Y-1,417.4%-498.5%-918.9%
4.3.2.2. Operating Ratio

Measures how efficient Aridis Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.56 means that the operating costs are $1.56 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aridis Pharmaceuticals Inc:

  • The MRQ is 1.558. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.558. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.558TTM1.5580.000
TTM1.558YOY28.476-26.918
TTM1.5585Y20.197-18.639
5Y20.19710Y16.741+3.457
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5582.465-0.907
TTM1.5583.253-1.695
YOY28.4763.298+25.178
5Y20.1974.788+15.409
10Y16.7416.494+10.247
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aridis Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aridis Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.32 means the company has $0.32 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aridis Pharmaceuticals Inc:

  • The MRQ is 0.315. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.315. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.315TTM0.3150.000
TTM0.315YOY0.804-0.488
TTM0.3155Y1.563-1.248
5Y1.56310Y3.219-1.656
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3153.637-3.322
TTM0.3153.890-3.575
YOY0.8044.666-3.862
5Y1.5635.953-4.390
10Y3.2196.277-3.058
4.4.3.2. Quick Ratio

Measures if Aridis Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aridis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.17 means the company can pay off $0.17 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aridis Pharmaceuticals Inc:

  • The MRQ is 0.166. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.166. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.166TTM0.1660.000
TTM0.166YOY0.606-0.441
TTM0.1665Y1.429-1.264
5Y1.42910Y3.120-1.691
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1663.086-2.920
TTM0.1663.451-3.285
YOY0.6064.456-3.850
5Y1.4295.931-4.502
10Y3.1206.436-3.316
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aridis Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aridis Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aridis Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.65 means that Aridis Pharmaceuticals Inc assets are financed with 264.9% credit (debt) and the remaining percentage (100% - 264.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aridis Pharmaceuticals Inc:

  • The MRQ is 2.649. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.649. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ2.649TTM2.6490.000
TTM2.649YOY1.527+1.122
TTM2.6495Y1.357+1.292
5Y1.35710Y1.158+0.199
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6490.350+2.299
TTM2.6490.344+2.305
YOY1.5270.310+1.217
5Y1.3570.365+0.992
10Y1.1580.382+0.776
4.5.4.2. Debt to Equity Ratio

Measures if Aridis Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aridis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aridis Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.379-1.379
5Y1.37910Y1.106+0.273
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.394-0.394
TTM-0.432-0.432
YOY-0.380-0.380
5Y1.3790.451+0.928
10Y1.1060.490+0.616
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aridis Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Aridis Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -1.71 means the investor is paying $-1.71 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aridis Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.711. Based on the earnings, the company is expensive. -2
  • The TTM is -1.711. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-1.711+1.710
MRQ-1.711TTM-1.7110.000
TTM-1.711YOY-2.242+0.532
TTM-1.7115Y-8.764+7.053
5Y-8.76410Y-5.477-3.286
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.253+2.253
MRQ-1.711-2.411+0.700
TTM-1.711-3.149+1.438
YOY-2.242-3.274+1.032
5Y-8.764-6.143-2.621
10Y-5.477-6.785+1.308
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aridis Pharmaceuticals Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.801. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.801. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-1.801+1.801
MRQ-1.801TTM-1.8010.000
TTM-1.801YOY-4.426+2.625
TTM-1.8015Y-12.565+10.764
5Y-12.56510Y-7.853-4.712
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.009+3.009
MRQ-1.801-3.259+1.458
TTM-1.801-3.730+1.929
YOY-4.426-4.574+0.148
5Y-12.565-8.371-4.194
10Y-7.853-9.287+1.434
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aridis Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -2.17 means the investor is paying $-2.17 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aridis Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the equity, the company is expensive. -2
  • The MRQ is -2.171. Based on the equity, the company is expensive. -2
  • The TTM is -2.171. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-2.171+2.170
MRQ-2.171TTM-2.1710.000
TTM-2.171YOY-7.361+5.190
TTM-2.1715Y6.528-8.699
5Y6.52810Y4.080+2.448
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0001.979-1.979
MRQ-2.1712.051-4.222
TTM-2.1712.365-4.536
YOY-7.3612.455-9.816
5Y6.5283.726+2.802
10Y4.0804.378-0.298
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aridis Pharmaceuticals Inc.

4.8.1. Institutions holding Aridis Pharmaceuticals Inc

Institutions are holding 10.379% of the shares of Aridis Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Wealth Architects, LLC0.03160.00021407700
2023-09-30State Street Corporation000-202247-100
2023-09-30Cornerstone Wealth Management LLC000-20000-100
2023-09-30ICA Group Wealth Management, LLC000-250-100
2023-09-30Wells Fargo & Co000-1459-100
2023-09-30Tower Research Capital LLC000-16363-100
2023-09-30Commonwealth Equity Services Inc000-646000-100
2023-09-30Northern Trust Corp000-28104-100
2023-09-30Roumell Asset Management, LLC000-446588-100
2023-09-30Group One Trading, LP000-2337-100
2023-09-30Vanguard Group Inc000-136197-100
2023-09-30Geode Capital Management, LLC000-143034-100
2023-09-30Vontobel Holding Ltd.000-50000-100
2023-09-30Virtu Financial LLC000-11809-100
2023-09-30BlackRock Inc000-4612-100
2023-09-30HRT FINANCIAL LLC000-73723-100
Total 0.03160.000214077-1782723-12,664.1%

4.9.2. Funds holding Aridis Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-29Roumell Opportunistic Value Instl1.00190.036744658800
Total 1.00190.036744658800.0%

5.3. Insider Transactions

Insiders are holding 18.046% of the shares of Aridis Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-07-27John F. HamiltonBUY20004.87
2021-07-27Vu TruongBUY50005.11
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Net Debt  -24,2373,340-20,89713,380-7,517-6,491-14,00815,2621,254



5.2. Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets14,695
Total Liabilities38,927
Total Stockholder Equity-24,232
 As reported
Total Liabilities 38,927
Total Stockholder Equity+ -24,232
Total Assets = 14,695

Assets

Total Assets14,695
Total Current Assets11,626
Long-term Assets3,069
Total Current Assets
Cash And Cash Equivalents 4,876
Net Receivables 1,240
Other Current Assets 5,510
Total Current Assets  (as reported)11,626
Total Current Assets  (calculated)11,626
+/-0
Long-term Assets
Property Plant Equipment 2,147
Intangible Assets 17
Long-term Assets Other 905
Long-term Assets  (as reported)3,069
Long-term Assets  (calculated)3,069
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities36,898
Long-term Liabilities2,029
Total Stockholder Equity-24,232
Total Current Liabilities
Short-term Debt 4,838
Short Long Term Debt 4,300
Accounts payable 2,308
Other Current Liabilities 9,579
Total Current Liabilities  (as reported)36,898
Total Current Liabilities  (calculated)21,025
+/- 15,873
Long-term Liabilities
Capital Lease Obligations 1,830
Long-term Liabilities  (as reported)2,029
Long-term Liabilities  (calculated)1,830
+/- 199
Total Stockholder Equity
Common Stock3
Retained Earnings -195,666
Accumulated Other Comprehensive Income 5,051
Other Stockholders Equity 166,380
Total Stockholder Equity (as reported)-24,232
Total Stockholder Equity (calculated)-24,232
+/-0
Other
Capital Stock3
Cash and Short Term Investments 4,876
Common Stock Shares Outstanding 18,777
Current Deferred Revenue20,173
Liabilities and Stockholders Equity 14,695
Net Debt 1,254
Net Invested Capital -19,932
Net Working Capital -25,272
Property Plant and Equipment Gross 4,190
Short Long Term Debt Total 6,130



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
> Total Assets 
3,884
22,537
26,478
31,611
27,967
15,117
26,796
14,695
14,69526,79615,11727,96731,61126,47822,5373,884
   > Total Current Assets 
3,567
22,409
25,340
24,237
27,967
15,117
26,796
11,626
11,62626,79615,11727,96724,23725,34022,4093,567
       Cash And Cash Equivalents 
2,892
22,291
25,096
24,237
20,897
8,232
19,986
4,876
4,87619,9868,23220,89724,23725,09622,2912,892
       Net Receivables 
522
67
0
1,660
413
368
237
1,240
1,2402373684131,660067522
       Other Current Assets 
0
51
244
2,450
4,527
4,155
6,055
5,510
5,5106,0554,1554,5272,450244510
   > Long-term Assets 
0
128
1,138
7,374
1,604
2,272
2,310
3,069
3,0692,3102,2721,6047,3741,1381280
       Property Plant Equipment 
42
39
750
1,271
1,006
1,258
1,357
2,147
2,1471,3571,2581,0061,2717503942
       Long Term Investments 
0
0
0
960
9
0
0
0
0009960000
       Intangible Assets 
54
48
43
38
32
27
22
17
1722273238434854
       Long-term Assets Other 
0
41
345
7,374
-1,047
-1,285
-1,379
905
905-1,379-1,285-1,0477,374345410
> Total Liabilities 
5,907
8,762
15,042
5,297
24,331
23,798
40,906
38,927
38,92740,90623,79824,3315,29715,0428,7625,907
   > Total Current Liabilities 
5,907
2,397
3,174
5,297
19,331
22,440
33,348
36,898
36,89833,34822,44019,3315,2973,1742,3975,907
       Short-term Debt 
3,681
0
0
2,489
0
439
696
4,838
4,83869643902,489003,681
       Short Long Term Debt 
3,681
0
0
0
0
439
696
4,300
4,30069643900003,681
       Accounts payable 
402
678
933
2,331
1,755
1,886
5,240
2,308
2,3085,2401,8861,7552,331933678402
       Other Current Liabilities 
146
1,719
2,121
455
2,974
1,367
6,574
9,579
9,5796,5741,3672,9744552,1211,719146
   > Long-term Liabilities 
0
6,365
11,868
0
5,000
1,358
6,558
2,029
2,0296,5581,3585,000011,8686,3650
       Long term Debt Total 
0
0
0
0
0
276
0
0
0027600000
       Other Liabilities 
0
6,365
11,868
0
5,000
1,358
1,276
0
01,2761,3585,000011,8686,3650
       Deferred Long Term Liability 
0
0
0
0
526
90
96
0
096905260000
> Total Stockholder Equity
-2,023
13,775
11,436
26,314
3,636
-8,681
-14,110
-24,232
-24,232-14,110-8,6813,63626,31411,43613,775-2,023
   Retained Earnings -195,666-165,295-123,102-100,769-71,088-47,626-20,177-11,290
   Accumulated Other Comprehensive Income 
0
-158
-215
-491
-823
0
0
5,051
5,05100-823-491-215-1580
   Capital Surplus 
-16,644
-24,945
-15,140
97,401
104,404
114,420
0
0
00114,420104,40497,401-15,140-24,945-16,644
   Treasury Stock00000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2022-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue19,250
Cost of Revenue-0
Gross Profit019,250
 
Operating Income (+$)
Gross Profit0
Operating Expense-29,993
Operating Income-29,993-29,993
 
Operating Expense (+$)
Research Development25,923
Selling General Administrative7,161
Selling And Marketing Expenses0
Operating Expense29,99333,084
 
Net Interest Income (+$)
Interest Income0
Interest Expense-378
Other Finance Cost-257
Net Interest Income-121
 
Pretax Income (+$)
Operating Income-29,993
Net Interest Income-121
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-30,371-29,615
EBIT - interestExpense = -30,371
-30,371
-30,371
Interest Expense378
Earnings Before Interest and Taxes (EBIT)-29,993-29,993
Earnings Before Interest and Taxes (EBITDA)-29,506
 
After tax Income (+$)
Income Before Tax-30,371
Tax Provision-0
Net Income From Continuing Ops-30,371-30,371
Net Income-30,749
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses29,993
Total Other Income/Expenses Net-378121
 

Technical Analysis of Aridis Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aridis Pharmaceuticals Inc. The general trend of Aridis Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aridis Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aridis Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0001 < 0.0001 < 0.0001.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Tweet this
Aridis Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aridis Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aridis Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aridis Pharmaceuticals Inc. The current macd is -0.00010.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aridis Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aridis Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aridis Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aridis Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAridis Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aridis Pharmaceuticals Inc. The current adx is 44.06.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aridis Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Aridis Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aridis Pharmaceuticals Inc. The current sar is 0.00554925.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aridis Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aridis Pharmaceuticals Inc. The current rsi is 25.98. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Aridis Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAridis Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aridis Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aridis Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aridis Pharmaceuticals Inc Daily Stochastic Oscillator ChartAridis Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aridis Pharmaceuticals Inc. The current cci is -41.66666667.

Aridis Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAridis Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aridis Pharmaceuticals Inc. The current cmo is -46.62572431.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aridis Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAridis Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aridis Pharmaceuticals Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Aridis Pharmaceuticals Inc Daily Williams %R ChartAridis Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aridis Pharmaceuticals Inc. The current atr is 0.00004.

Aridis Pharmaceuticals Inc Daily Average True Range (ATR) ChartAridis Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aridis Pharmaceuticals Inc. The current obv is 205,237,920.

Aridis Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAridis Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aridis Pharmaceuticals Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aridis Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAridis Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aridis Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Aridis Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aridis Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.976
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.003
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aridis Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Aridis Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aridis Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aridis Pharmaceuticals Inc

I send you an email if I find something interesting about Aridis Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aridis Pharmaceuticals Inc.

Receive notifications about Aridis Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.